Diabetes drug cuts repeat heart attacks-study
DALLAS (Reuters) – A diabetes drug sold by Takeda
Pharmaceutical Co. and Eli Lilly and Co. significantly cut the
rate of a second heart attack compared with a placebo in
high-risk patients with type-2 diabetes, a study reported on
The data come from a secondary analysis of a failed trial
of the drug Actos reported in September, which had a more
ambitious main goal of preventing a wider range of
cardiovascular incidents, including death, stroke, and heart
attack in high-risk type-2 diabetics.
The data presented at the American Heart Association annual
scientific meeting show that Actos, also known as pioglitazone,
reduced the risk of repeat heart attacks by 28 percent,
according to researchers who conducted the 2,445-patient study.